4728.TWO Sunmax Biotechnology Co Ltd
- Market cap
- TWD 21.3B
- P/E
- 26.2x
- P/B
- 14.81x
- ROE
- 64.9%
- Dividend yield
- 2.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4728.TWO undervalued?
Graham numberThe Graham number of Sunmax Biotechnology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sunmax Biotechnology Co Ltd fundamental analysis
No fundamental analysis for Sunmax Biotechnology Co Ltd yet.
Sunmax Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.
Full company profileSunmax Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sunmax Biotechnology Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 156M | 190M | 304M | 594M | 856M | 1.04B | 1.40B | 1.69B | 1.82B | 2.03B | 2.37B |
| Gross Profit | 99.1M | 138M | 240M | 514M | 701M | 894M | 1.19B | 1.40B | 1.48B | 1.59B | 1.90B |
| Operating Income | 3.10M | 13.3M | 63.9M | 178M | 346M | 363M | 778M | 912M | 927M | 998M | 1.24B |
| EBITDA | - | 22.2M | 71.2M | 171M | 380M | 418M | 836M | 985M | 1.06B | 1.12B | 1.40B |
| Net Income | 1.74M | 16.5M | 74.7M | 100M | 238M | 246M | 534M | 626M | 679M | 726M | 928M |
| EPS | - | 0.31 | 1.37 | 1.84 | 4.37 | 4.51 | 9.79 | 11 | 12 | 13 | 17 |
| Balance Sheet | |||||||||||
| Total Assets | 597M | 661M | 758M | 1.11B | 1.36B | 1.48B | 1.79B | 2.16B | 2.09B | 2.12B | 2.00B |
| Total Liabilities | 42.2M | 88.2M | 110M | 436M | 475M | 460M | 468M | 733M | 582M | 506M | 570M |
| Shareholders' Equity | 555M | 573M | 648M | 677M | 889M | 1.02B | 1.33B | 1.43B | 1.51B | 1.62B | 1.43B |
| Cash & Short-term Investments | 435M | 314M | 314M | 583M | 910M | 679M | 817M | 962M | 775M | 712M | 430M |
| Total Debt | - | - | - | - | 136M | 109M | 70.3M | 174M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.6M | 37.1M | 101M | 290M | 387M | 243M | 343M | 849M | 561M | 826M | 1.08B |
| Capital Expenditure | 4.73M | 3.15M | 4.72M | 13.7M | 130M | 255M | 152M | 110M | 37.0M | 68.3M | 74.1M |
| Free Cash Flow | - | 33.4M | 96.0M | 271M | 257M | -12.1M | 191M | 738M | 524M | 758M | 1.00B |
| Ratios | |||||||||||
| ROE | 0.3% | 2.9% | 11.5% | 14.8% | 26.8% | 24.0% | 40.3% | 43.9% | 44.9% | 44.9% | 64.9% |
| ROA | 0.3% | 2.5% | 9.9% | 9.0% | 17.5% | 16.6% | 29.8% | 29.0% | 32.4% | 34.2% | 46.4% |
| Net Profit Margin | 1.1% | 8.7% | 24.6% | 16.9% | 27.8% | 23.7% | 38.1% | 37.0% | 37.4% | 35.8% | 39.2% |
| Debt to Equity | - | - | - | - | 0.15x | 0.11x | 0.05x | 0.12x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sunmax Biotechnology Co Ltd dividends
- Dividend yield
- 2.97%
- Forward dividend
- 12.10 TWD
- Payout ratio
- 87.1%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 632M | 12 | 87.1% |
| 2024 | TWD 599M | 11 | 88.2% |
| 2023 | TWD 517M | 9.49 | 82.7% |
| 2022 | TWD 240M | 4.39 | 44.9% |
| 2021 | TWD 109M | 2.00 | 44.3% |
| 2020 | TWD 81.7M | 1.50 | 34.3% |
| 2019 | TWD 65.4M | 1.20 | 65.1% |
| 2018 | TWD 16.2M | 0.30 | 21.7% |
| 2017 | TWD 16.2M | 0.30 | 98.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sunmax Biotechnology Co Ltd
- Insiders 37.57%
- Institutions 0.69%
- Public & others 61.75%
- Shares outstanding 54.5M
- Free float 27.1M
Sunmax Biotechnology Co Ltd company profile
- Company name
- Sunmax Biotechnology Co Ltd
- Ticker
- 4728.TWO
- ISIN
- TW0004728001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 10, Huandong Road, Tainan City, Taiwan, 744
- Phone
- 886 6 505 3288
- Website
- sunmaxbiotech.com
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of biomedical-grade collagen and related products in Taiwan, Mainland China, and internationally. It offers collagen dermal filler sets, such as Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO injectable collagen gel with lidocaine. The company was founded in 2001 and is based in Tainan City, Taiwan.
Sunmax Biotechnology Co Ltd management
2- Mr. Ming Yi LinManager
- Shi Xing ZhuangAccounting Supervisor